Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Grabar Law Office Investigates Claims on Behalf of Shareholders of PACS Group, Inc. (PACS)

PACS

Philadelphia, Pennsylvania--(Newsfile Corp. - January 14, 2025) - Grabar Law Office is investigating claims on behalf of PACS Group, Inc. (NYSE: PACS) shareholders. If you are a current shareholder who purchased PACS shares on or near the Company's April 11, 2024 IPO, you may be able to seek corporate reforms, the return of money back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/pacs-shareholder-investigation/ at jgrabar@grabarlaw.com, or call 267-507-6085.

WHY? On November 4, 2024, investment research firm Hindenburg Research published a report that accused PACS Group, Inc. of engaging in fraudulent practices. A federal securities fraud class action Complaint followed in which it is alleged that in the Registration Statement and throughout the Class Period (April 11, 2024 to November 5, 2024), PACS Group, through certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, it is alleged that Defendants failed to disclose to investors: (1) that the Company engaged in a "scheme" to submit false Medicare claims which "drove more than 100% of PACS' operating and net income from 2020 - 2023"; (2) that the Company engaged in a "scheme" to "bill thousands of unnecessary respiratory and sensory integration therapies to Medicare"; (3) that the Company engaged in a scheme to falsify documentation related to licensure and staffing; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT YOU CAN DO NOW: If you purchased PACS shares on or near the April 11, 2024 IPO, you are encouraged to visit https://grabarlaw.com/the-latest/pacs-shareholder-investigation/, contact us at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

#PACS #PACSGroup $PACS

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/237133